Journal
CLINICAL CASE REPORTS
Volume 9, Issue 4, Pages 1933-1936Publisher
WILEY
DOI: 10.1002/ccr3.3909
Keywords
acute myeloid leukemia; CPX-351; elderly; rash
Categories
Funding
- Erasmus + study grant
Ask authors/readers for more resources
CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia, can cause a severe whole-body rash. While severe side effects are rare, treatment should be carefully monitored at specialized centers.
CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
